How can a clinical consultant help my drug development program?
Clinical navigation consultants help pharmaceutical, biotechnology, and medical device companies minimize drug development risks, optimize timelines and costs, improve regulatory success rates, and inspire confidence among decision-makers and potential partners.
What makes PharPoint different?
PharPoint is a contract research organization (CRO) with consultative roots. With over 1,000 clinical trials supported in the last 15+ years, our team is equipped to help sponsors make informed decisions to expedite their clinical development programs and ensure quality science.
Get strategic support as you prepare your clinical strategy
Find the right path forward, identify and overcome potential clinical trial challenges and meet your study goals the first time around.
With deep clinical trial expertise and a consultative approach, the PharPoint team can provide strategic support to help guide pharmaceutical, biotechnology, and medical device companies as they develop their drug development programs – from pre-IND planning through regulatory approval.
Program Strategy
Receive high-level strategic program support, including:
- IND submission support/module development
- Strategic development planning and maintenance
- Program review support
Regulatory Strategy
Partner with regulatory experts to lay out a pathway to approval, including:
- Regulatory strategy development/review
- Expedited pathway exploration
- Regulatory meeting support and representation
Trial Planning and Conduct
Get insight and support from a team that has participated in over 1,000 clinical trials, including:
- Protocol design
- Phase 1-4 clinical trial planning
- Risk mitigation
- Key Opinion Leader (KOL) network development
- Investigative site feasibility
EXPLORE RELATED RESOURCES
Navigate the complexities of drug development
With support from PharPoint’s clinical navigation consultants and a comprehensive clinical development plan guiding decision-making in their toolkit, life sciences companies can bring innovative medicines through the drug development pipeline faster – because patients are waiting.
